Source comparison
Melanotan-2 Study: Comparison of Trial Dosages and Outcomes
Phase I (Levine et al., 1991) 0.05–0.25mg/kg SC Safety and tolerability 5–7 days without UV 35% nausea, 20% flushing Small sample (n=20), single-dose only Phase II (Dorr et al., 2000) 0.16mg/kg SC daily × 10 days Melanogenesis and photoprotection 3–5 days with
This comparison does not assign a generated winner or score.
- Phase I (Levine et al., 1991)
- 0.05–0.25mg/kg SC
- Safety and tolerability
- 5–7 days without UV
- 35% nausea, 20% flushing
- Small sample (n=20), single-dose only
- Phase II (Dorr et al., 2000)
- 0.16mg/kg SC daily × 10 days
- Melanogenesis and photoprotection
- 3–5 days with minimal UV
- 60% nausea, 72% spontaneous erections (males)
- No long-term follow-up beyond 12 weeks
- Phase II (Wessells et al., 2000)
- 0.025mg/kg SC 3× weekly
- Erectile function in ED patients
- Not assessed (ED trial)
- 40% nausea, facial flushing in 55%
- Trial halted early due to high discontinuation
- Animal Model (mice)
- 1–10mg/kg SC daily × 90 days
- Carcinogenicity and toxicity
- N/A (pigmentation not measured)
- 15% mortality at highest dose, hepatotoxicity noted
- Cannot extrapolate directly to human dosing
- Observational (user-reported)
- 0.25–2.0mg SC 2–3× weekly
- Aesthetic tanning (non-clinical)
- 2–4 days
- Self-reported rates vary widely (50–80% nausea)
- No controlled environment, dosing accuracy unknown
- Professional Assessment
- Trial data stops at Phase II. Long-term safety undefined. Non-clinical use exceeds studied dosages by 2–4× in many cases. Lack of FDA oversight means peptide purity, sterility, and accurate dosing cannot be verified outside research-grade suppliers.